For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other ...

Biocon Biologics, a fully integrated global biosimilars company and subsidiary of India’s Biocon Ltd, announced that it has ...

Indian drugmaker Biocon has announced the signing of an out-licensing agreement with Ajanta Pharma to market its vertically ...

As per the exchange filing, Biocon Biologics will take responsibility across the product lifecycle, which includes ...

Ajanta Pharma has signed an in-licensing pact with Biocon to commercialise semaglutide in 26 countries across Africa, the ...

Biocon Biologics secures global rights for biosimilar Adalimumab (Hulio) from Fujifilm Kyowa Kirin. Full manufacturing & ...

Biocon Biologics Ltd obtains full exclusive global rights for Hulio, a biosimilar Adalimumab, from Fujifilm Kyowa Kirin ...

According to PL Capital, Ajanta Pharma's strong franchise will aid in garnering a higher market share for semaglutide ...

Under the agreement, Biocon will supply semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive ...

Pharmaceutical stocks are back in focus with strong stock-specific triggers. Ajanta Pharma has gained attention after signing ...

Ajanta Pharma plans to sell generic semaglutide in 26 countries, in a partnership with Biocon, capitalizing on patent ...

Ajanta Pharma secures exclusive rights to market Biocon's semaglutide in 26 countries, targeting growth in diabetes and ...